These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 12923828)

  • 1. Differential period of onset of action of fluvoxamine, paroxetine and milnacipran for depression.
    Morishita S; Arita S
    Hum Psychopharmacol; 2003 Aug; 18(6):479-82. PubMed ID: 12923828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential effects of fluvoxamine, paroxetine and milnacipran for depression, especially with regard to age.
    Morishita S; Arita S
    Hum Psychopharmacol; 2004 Aug; 19(6):405-8. PubMed ID: 15303244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gender differences in the clinical effects of fluvoxamine and milnacipran in Japanese major depressive patients.
    Naito S; Sato K; Yoshida K; Higuchi H; Takahashi H; Kamata M; Ito K; Ohkubo T; Shimizu T
    Psychiatry Clin Neurosci; 2007 Aug; 61(4):421-7. PubMed ID: 17610668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effects of milnacipran, fluvoxamine and paroxetine for depression, especially in gender.
    Morishita S; Arita S
    Eur Psychiatry; 2003 Dec; 18(8):418-20. PubMed ID: 14680720
    [No Abstract]   [Full Text] [Related]  

  • 5. Induction of mania in depression by paroxetine.
    Morishita S; Arita S
    Hum Psychopharmacol; 2003 Oct; 18(7):565-8. PubMed ID: 14533140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of antidepressants on plasma metabolites of nitric oxide in major depressive disorder: comparison between milnacipran and paroxetine.
    Ikenouchi-Sugita A; Yoshimura R; Hori H; Umene-Nakano W; Ueda N; Nakamura J
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Nov; 33(8):1451-3. PubMed ID: 19664676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sertraline treatment of patients with major depressive disorder who failed initial treatment with paroxetine or fluvoxamine.
    Inoue T; Honda M; Kawamura K; Tsuchiya K; Suzuki T; Ito K; Matsubara R; Shinohara K; Ishikane T; Sasaki K; Boku S; Fujisawa D; Ono Y; Koyama T
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Aug; 38(2):223-7. PubMed ID: 22504727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antidepressant efficacy and tolerability of milnacipran, a dual serotonin and noradrenaline reuptake inhibitor: a comparison with fluvoxamine.
    Clerc G;
    Int Clin Psychopharmacol; 2001 May; 16(3):145-51. PubMed ID: 11354236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparative study of milnacipran and imipramine in the treatment of major depressive disorder.
    Lopez-Ibor JJ; Conesa A;
    Curr Med Res Opin; 2004 Jun; 20(6):855-60. PubMed ID: 15200743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A case with occurring adverse effects when cross-over titration from fluvoxamine to paroxetine associated with increasing the plasma fluvoxamine level in major depressive disorder.
    Hori H; Yoshimura R; Ueda N; Ikenouchi-Sugita A; Umene-Nakano W; Nakamura J
    World J Biol Psychiatry; 2009; 10(4 Pt 2):620-2. PubMed ID: 18609433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial.
    Jahn H; Schick M; Kiefer F; Kellner M; Yassouridis A; Wiedemann K
    Arch Gen Psychiatry; 2004 Dec; 61(12):1235-44. PubMed ID: 15583115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suitable dose and duration of fluvoxamine administration to treat depression.
    Morishita S; Arita S
    Psychiatry Clin Neurosci; 2003 Apr; 57(2):177-81. PubMed ID: 12667164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resolution of sexual dysfunction during acute treatment of major depression with milnacipran.
    Baldwin D; Moreno RA; Briley M
    Hum Psychopharmacol; 2008 Aug; 23(6):527-32. PubMed ID: 18536065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of efficacy and safety of milnacipran and fluoxetine in Korean patients with major depression.
    Lee MS; Ham BJ; Kee BS; Kim JB; Yeon BK; Oh KS; Oh BH; Lee C; Jung HY; Chee IS; Choe BM; Paik IH
    Curr Med Res Opin; 2005 Sep; 21(9):1369-75. PubMed ID: 16197655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic variants in combination with early partial improvement as a clinical utility predictor of treatment outcome in major depressive disorder: the result of two pooled RCTs.
    Kato M; Serretti A; Nonen S; Takekita Y; Wakeno M; Azuma J; Kinoshita T
    Transl Psychiatry; 2015 Feb; 5(2):e513. PubMed ID: 25710119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bcl1 polymorphism of the glucocorticoid receptor gene and treatment response to milnacipran and fluvoxamine in Japanese patients with depression.
    Takahashi H; Yoshida K; Higuchi H; Kamata M; Inoue K; Suzuki T; Ishigooka J
    Neuropsychobiology; 2014; 70(3):173-80. PubMed ID: 25358426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antidepressant response in the elderly.
    Mandelli L; Serretti A; Zanardi R; Rossini D; De Ronchi D; Tarricone I; Colombo C
    Psychiatry Res; 2007 Jul; 152(1):37-44. PubMed ID: 17383015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential effects of milnacipran, fluvoxamine and paroxetine for inhibited and agitated depression.
    Morishita S; Arita S
    Eur Psychiatry; 2004 Nov; 19(7):450-1. PubMed ID: 15504656
    [No Abstract]   [Full Text] [Related]  

  • 19. No predictors of antidepressant patient response to milnacipran were obtained using the three-factor structures of the Montgomery and Asberg Depression Rating Scale in Japanese patients with major depressive disorders.
    Higuchi H; Sato K; Yoshida K; Takahashi H; Kamata M; Otani K; Yamaguchi N
    Psychiatry Clin Neurosci; 2008 Apr; 62(2):197-202. PubMed ID: 18412843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparative study of milnacipran and paroxetine in outpatients with major depression.
    Sechter D; Vandel P; Weiller E; Pezous N; Cabanac F; Tournoux A;
    J Affect Disord; 2004 Dec; 83(2-3):233-6. PubMed ID: 15555719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.